Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $49

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $28 to $49.